Substituted Cyclopentane Compounds for Ocular Pressure Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly those involving ocular hypotensive agents, face challenges in effectively reducing intraocular pressure and managing the condition, especially in cases of primary and secondary glaucoma where the underlying causes are not well understood and traditional drugs like β-adrenoreceptor antagonists have limitations.
Innovation Solution
Development of specific compounds with a formula that includes an organic acid functional group, amide, ester, hydroxymethyl, or tetrazolyl functional group, which are incorporated into a medicament for topical administration to reduce intraocular pressure and treat glaucoma, offering various stereoisomers and structural variations for optimal efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional β-adrenoreceptor antagonists are used to treat glaucoma, then intraocular pressure can be reduced to some extent, but the treatment effectiveness is limited and side effects occur
Solution Approach 1:
The patent changes the chemical structure parameters by introducing a cyclopentane ring with specific substituents (fluorine, chlorine, hydroxyl groups) and varying chain lengths and configurations to optimize the balance between therapeutic effectiveness and reduction of harmful side effects associated with traditional β-adrenoreceptor antagonists
Solution Approach 2:
The patent creates composite molecular structures combining cyclopentane core with various functional groups (carboxylic acid, amide, ester, hydroxymethyl, tetrazolyl) and aromatic substituents to achieve enhanced therapeutic properties while minimizing adverse effects
2Reliability
If prostaglandins and their derivatives are used for glaucoma management, then intraocular pressure reduction is achieved, but the structural complexity and limitations in efficacy remain
Solution Approach 1:
The patent extracts and isolates the essential cyclopentane core structure from the complex prostaglandin molecular framework, retaining the key functional groups needed for ocular hypotensive activity while eliminating unnecessary structural complexity
Solution Approach 2:
The patent segments the molecular structure into distinct functional modules: a cyclopentane core with specific stereochemistry, variable chain lengths (A moiety), and interchangeable terminal groups (Y and B), allowing optimization of each segment independently to achieve desired therapeutic effects with reduced overall complexity
3Adaptability or versatility
If various prostaglandin types with different substituents are used, then different ocular hypotensive effects are achieved, but the difficulty in selecting the optimal compound increases
Solution Approach 1:
The patent creates a universal cyclopentane-based molecular platform that can accommodate multiple functional groups and substituent patterns, providing a single versatile structure capable of delivering various ocular hypotensive effects through systematic modification of R groups and chain lengths rather than requiring entirely separate compound classes
Data Source
AI summary
Disclosed herein are compounds having the formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ether thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis —CH2CH═CH—(CH2)3—, or —CH2C═C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o— wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 —CH2— may be replaced by S or O, and 1 —CH2—CH2— may be replaced by —CH═CH— or —C≡C—; U1 and U2 are independently selected from —H, ═O, —OH, —F, —Cl, and —CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.